0001562180-24-005752.txt : 20240716
0001562180-24-005752.hdr.sgml : 20240716
20240716162408
ACCESSION NUMBER: 0001562180-24-005752
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240712
FILED AS OF DATE: 20240716
DATE AS OF CHANGE: 20240716
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GUYER DAVID R
CENTRAL INDEX KEY: 0001277476
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 241119914
MAIL ADDRESS:
STREET 1: ONE PENN PLAZA, 19TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10119
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-07-12
false
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001277476
GUYER DAVID R
C/O EYEPOINT PHARMACEUTICALS, INC.
480 PLEASANT STREET
WATERTOWN
MA
02472
true
false
false
false
true
Common Stock
2024-07-12
4
M
false
3250.00
3.50
A
6950.00
D
Common Stock
2024-07-12
4
M
false
6525.00
3.26
A
13475.00
D
Common Stock
2024-07-12
4
S
false
11625.00
10.0641
D
1850.00
D
Stock Option (Right to Buy)
3.50
2024-07-12
4
M
false
3250.00
0.00
D
2024-02-23
2033-06-19
Common Stock
3250.00
3250.00
D
Stock Option (Right to Buy)
3.26
2024-07-12
4
M
false
6525.00
0.00
D
2024-01-06
2033-06-19
Common Stock
6525.00
6525.00
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.125. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Ron Honig, Attorney-in-Fact
2024-07-16